S
umatriptan, a 5-HT derivative with agonist activity at 5-HT 1B/1D receptors, is highly effective in aborting attacks of migraine and cluster headache. The drug is generally well tolerated. However, up to 15% of patients consistently report chest symptoms, including chest pressure, tightness, and pain, often mimicking angina pectoris. [1] [2] [3] Although extracardiac mechanisms have been invoked, 4 chest symptoms may well be caused by coronary vasoconstriction, which has been observed after sumatriptan both in vivo 5 and in vitro. [6] [7] [8] In some cases, the use of sumatriptan, like that of ergotamine, 9 -11 was even associated with myocardial infarction 12, 13 and cardiac arrest. 14 "Secondgeneration" sumatriptan-like antimigraine drugs are all aimed at, in addition to achieving high efficacy and long duration of action, avoiding coronary vasoconstrictor activity. 15 The present study deals with 2 major issues in clinical practice: (1) Do new antimigraine compounds cause less coronary artery constriction than sumatriptan? and (2) Is sumatriptan better than ergot derivatives in this respect? Obviously, these questions cannot be easily answered by clinical trials. We therefore employed a pharmacological approach using the human isolated coronary artery to determine the potency (sensitivity) and efficacy (magnitude) of the contractile responses to sumatriptan and other current (ergotamine, dihydroergotamine, methysergide, and its active metabolite methylergometrine 16 ) as well as new (naratriptan, 17 zolmitriptan, 18, 19 rizatriptan, 20 and avitriptan 21 ) antimigraine drugs. Results were related to the respective C max reported in patients.
Because sumatriptan-induced contractions of coronary arteries show substantial variability both within and between studies, 22, 23 we used a "parallel" experimental design involving segments from the same coronary artery. These coronary arteries were obtained from organ donors who died of causes unrelated to cardiac diseases and therefore may potentially represent the population treated with antimigraine drugs.
Methods

Preparation of Tissue
Right epicardial coronary arteries were obtained from 14 "heart beating" organ donors (7 male, 7 female; age, 7 to 61 years) who died of noncardiac disorders (11 of cerebrovascular accident, 3 of head trauma) Ͻ24 hours before the tissue was taken to the laboratory. Hearts were provided by the Rotterdam Heart Valve Bank (Bio Implant Services/Eurotransplant Foundation) after removal of the aortic and pulmonary valves for transplantation purposes. The study was approved by the joint Ethical Committee of the Erasmus University Rotterdam and the University Hospital Rotterdam "Dijkzigt." The hearts were stored at 0°C to 4°C in a sterile organ-protecting solution immediately after circulatory arrest. After arrival in the laboratory, the right coronary artery was removed and placed in a cold, 
Experimental Protocol
After equilibration for at least 30 minutes and a wash every 15 minutes, changes in tissue force were recorded with a Harvard isometric transducer. The vessel segments, stretched to a stable force of Ϸ15 mN, were exposed to 30 mmol/L K ϩ twice, and the functional integrity of the endothelium was verified by observation of relaxation to substance P (1 nmol/L) after precontraction with PGF 2␣ (1 mol/L). The tissue was washed and then exposed to 100 mmol/L K ϩ . The data obtained with PGF 2␣ , substance P, and 100 mmol/L K ϩ were averaged for each coronary artery. Subsequently, the vessel segments were washed again and, after a 30-minute equilibration period, 2 series of experiments were performed.
Concentration-Response Curves and Relation With Clinical Plasma Concentrations
In the first series of 9 experiments, a concentration-response curve was constructed with the different compounds (ergotamine, dihydroergotamine, methysergide, methylergometrine, sumatriptan, naratriptan, rizatriptan, avitriptan, and zolmitriptan, as well as 5-HT used as a marker). In some cases, concentration-response curves to sumatriptan were obtained in duplicate, which were averaged and regarded as one curve in further analysis. As described earlier in detail, 23 contractile responses were expressed as a percentage of the contraction induced by 100 mmol/L K ϩ in the respective segments, and the data were analyzed to obtain, in each case, values of E max and EC 50 . The E max and EC 50 values represent the efficacy and potency, respectively, of a drug in eliciting a response (in this case, coronary artery contraction). Thus, the lower the EC 50 of a drug, the more likely it is to cause coronary vasoconstriction at lower plasma concentrations; the E max is obviously only of importance when a drug is present in high enough concentrations, as dictated by its potency. To assess the capacity of various agonists to contract the human coronary artery during clinical use in migraine, we calculated the ratio between the reported C max after administration of clinically effective doses (Table) and the EC 50 value of the compounds in contracting the human isolated coronary artery. Thus, a high C max / EC 50 ratio indicates that the plasma concentration of the drug is high enough to contract the human coronary artery in the clinical situation. The magnitude of this contraction will be dictated by the E max of the drug.
Duration of Action
In a second series of 5 experiments, the durations of action of the acutely acting antimigraine drugs (ergotamine, dihydroergotamine, sumatriptan, naratriptan, rizatriptan, avitriptan, and zolmitriptan) were compared. For this purpose, contractions of coronary artery segments were elicited with a single concentration of these drugs (2 times EC 50 , as determined in the first series of experiments), and the time to reach a stable contraction was noted. The segments were then washed twice every 15 minutes, and contractions remaining after each wash were noted for a total period of 90 minutes.
Analysis of Data
Differences between EC 50 and E max values of sumatriptan and other compounds as well as between contractions remaining after each wash (every 15 minutes) were evaluated with Duncan's new multiple range test, once an ANOVA (randomized block design) had revealed that the samples represented different populations. The E max of the compounds tested was correlated with the relaxant response to substance P obtained in the individual coronary arteries (Pearson's 
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Results
Basic Properties of the Preparations: Effects of Substance P and Potassium
All coronary artery segments, obtained from 14 hearts, relaxed after substance P (1 nmol/L), the response amounting to 61Ϯ8% of the precontraction (35Ϯ2 mN) to PGF 2␣ (1 mol/L). Contraction to 100 mmol/L KCl was 47Ϯ3 mN.
Concentration-Response Curves and Relation With Substance P Response and Clinical Plasma Concentrations
Concentration-response curves obtained in 9 coronary arteries with the various compounds investigated are shown in Figure 1 , and the derived values of EC 50 (nmol/L) and E max (% of contraction elicited by 100 mmol/L K ϩ ) are shown in the Table. As reported earlier, 22, 23 the contractile effect of sumatriptan on the isolated human coronary artery showed a considerable variability; the EC 50 and E max values ranged from 117 to 2042 nmol/L and 2.3% to 27.0% of the response to 100 mmol/L K ϩ , respectively. The EC 50 values of all compounds, in particular ergotamine, dihydroergotamine, and methylergometrine, were significantly lower than that of sumatriptan. The E max of 5-HT was significantly higher, but those of the other compounds did not differ significantly from that of sumatriptan. However, it may be noted that the E max of other triptan derivatives is about half that of ergotamine.
In the 9 hearts in which concentration-response curves to the antimigraine agents were constructed, the correlation between the E max of the drugs and the coronary artery relaxation to substance P (1 nmol/L) after precontraction with PGF 2␣ (1 mol/L) was assessed. Pearson's correlation coefficient did not yield a significant P value with any of the drugs (data not shown). Figure 2 depicts the ratio between the reported plasma C max obtained after administration of a clinically effective dose (see Table) and the EC 50 value of the compounds in contracting the human isolated coronary artery. The data show that, compared with that of 100 mg PO sumatriptan, the C max /EC 50 ratios of avitriptan (75 and 150 mg PO) were higher, those of ergotamine (2 mg PO) and zolmitriptan (2.5 and 5 mg PO) were lower, and those of the other compounds (naratriptan, rizatriptan, and methysergide measured as its active metabolite methylergometrine) were in the same range. The ranges of C max /EC 50 ratios obtained with parenteral ergotamine (0.5 mg IM) and dihydroergotamine (1 mg SC) were not much different from that with parenteral sumatriptan (6 mg SC).
Duration of Action
Contractions to a single concentration (2 times EC 50 ) of the acutely acting antimigraine drugs were elicited in 5 coronary arteries. The peak stable contraction (% of 100 mmol/L K ϩ ) and the time required to reach the peak contraction with the different compounds were as follows: sumatriptan 15Ϯ4% (3Ϯ2 minutes), naratriptan 10Ϯ3% (3Ϯ1 minutes), zolmitriptan 21Ϯ15% (4Ϯ7 minutes), rizatriptan 22Ϯ16% (4Ϯ2 minutes), avitriptan 17Ϯ12% (5Ϯ1 minutes), ergotamine 26Ϯ7% (24Ϯ13 minutes), and dihydroergotamine 27Ϯ11% (18Ϯ10 minutes). The effects of repeated washings on the peak contractions elicited by each drug are presented in Figure 3 . The data show that the contractile responses to ergotamine and dihydroergotamine were sustained over the 90-minute period (PՅ0.05 versus sumatriptan), whereas those to sumatriptan, naratriptan, rizatriptan, avitriptan, and zolmitriptan nearly completely disappeared after the second wash 30 minutes later.
Discussion Human Coronary Artery Contraction In Vitro
As reported earlier in vitro 6, 8, 24 and in vivo, 25 ,26 5-HT induced contraction of the human isolated coronary artery. 5-HT was Table  for references) are indicated in each case, except methylergometrine (measured after methysergide, 2 mg PO). When lower and upper values are mentioned, they indicate reported range. Note that a C max /EC 50 ratio of 1 indicates that, if same conditions were applicable in patients as in present in vitro experiments, drug would elicit 50% of its maximum contraction of coronary artery. In view of use of C max data from literature, C max /EC 50 ratios of different drugs were not subjected to statistical analysis.
more efficacious (higher E max value) than sumatriptan, because of a more prominent action mediated via 5-HT 2 receptors. 6, 8, 24, 26 With respect to the antimigraine compounds, the results of our study show that all drugs, but in particular ergotamine, dihydroergotamine, and methylergometrine (metabolite of methysergide 16 ), were more potent (lower EC 50 values) than sumatriptan in contracting the human isolated coronary artery. Although the E max of ergotamine tended to be somewhat higher than that of sumatriptan, we observed no statistically significant differences between E max values of sumatriptan and any of the other antimigraine drugs. Our findings are in agreement with a recent report on zolmitriptan, 19 but they appear to be at variance with earlier studies claiming that rizatriptan is only half as effective as sumatriptan in contracting the human isolated coronary artery. 27, 28 Admittedly, data obtained in human post mortem tissues can vary between experiments because of a variety of factors, which are difficult to discern. However, the coronary arteries used in these studies 27, 28 were endothelium-denuded and obtained from hearts from patients undergoing cardiac transplantation. In contrast, the coronary arteries in the present experiments were obtained from organ donors who died of noncardiac causes, and the endothelium was not removed. Thus, our population may better reflect the population likely to be treated with 5-HT 1B/1D receptor agonists.
Coronary Artery Contraction and Relaxation to Substance P
It is suggested that relaxation to substance P is a measure of the functional integrity of the endothelium and could be related to underlying coronary artery disease. 29, 30 Because there was no significant correlation between the E max of the compounds and relaxant response to substance P in the coronary arteries used in the present investigation, it would appear that the contractile effect of the antimigraine drugs is not increased by underlying coronary artery disease. We concede that the present study, with few data points at the outer sides of the range of the relaxant response to substance P, may not be particularly suitable for such an analysis. However, even in a larger analysis (78 donor hearts), we did not find an inverse but rather in fact a positive correlation between the E max of sumatriptan and the magnitude of substance P relaxation in the human coronary artery.
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Coronary Artery Contraction at Therapeutic Plasma Concentrations
We calculated the ratio between the clinically effective plasma C max and EC 50 values of the different antimigraine compounds to estimate the degree of coronary vasoconstriction to be expected during therapeutic use (see Figure 2) . Except for avitriptan, the plasma C max values of all drugs tested remain Ͻ40%, and in the case of zolmitriptan, ergotamine (2 mg PO), and methysergide (but note, not its metabolite methylergometrine), even Ͻ10% of their EC 50 values. Thus, with the exception perhaps of avitriptan, therapeutic doses of the antimigraine drugs investigated will cause little coronary artery constriction in vivo. It was recently shown with PET that sumatriptan did not affect myocardial perfusion in healthy migraineurs at therapeutic plasma concentrations. 32 Even in the case of avitriptan, the maximum coronary constriction (E max Ϸ8% of 100 mmol/L K ϩ response) will be barely perceptible and is unlikely to affect coronary artery blood flow, which remains unchanged until the arterial lumen is compromised by Ͼ80%. 33 In contrast, in patients with preexisting coronary artery lesions who have only a limited coronary reserve, 33 even a small coronary artery contraction that may occur with plasma concentrations encountered during clinical use could be enough to cause myocardial ischemia. A similar phenomenon may also be observed in patients with "variant" angina pectoris, who have increased coronary artery sensitivity to 5-HT. 26 It has been reported that the contractile effect of sumatriptan on the human isolated coronary artery is potentiated by thromboxane A 2 23,34 and is inhibited by aspirin as well as the thromboxane receptor antagonist SQ30741. 23 Thus, exaggerated production of such substances locally may augment coronary artery contractions to similar antimigraine drugs in vivo.
Additional Factors Involved in Coronary Artery Constriction in Patients
Other factors involved in the contraction of coronary arteries in vivo are slow diffusion from the receptor biophase, plasma protein binding, and the formation of active metabolites. Slow diffusion from the receptor biophase, which has been reported for ergot derivatives, 35 is in accordance with our findings concerning the sustained response to both ergotamine and dihydroergotamine despite repeated washings (Figure 3) . In the clinical situation, it is also known that the effects of ergotamine and dihydroergotamine sustain much longer than is to be expected from their plasma concentration profiles. [35] [36] [37] Indeed, substernal chest pain and discomfort suggestive of myocardial infarction have repeatedly been described with ergot preparations, particularly ergotamine. 10, 38 Dihydroergotamine, 39 methysergide, 16 and possibly ergotamine 38 form active metabolites, which, as is clearly the case with methysergide (see results with methylergometrine), may also cause coronary artery constriction. Sumatriptan does not have active metabolites, 40 but zolmitriptan forms an N-desmethyl derivative, which is approximately twice as Figure 3 . Effect of repeated washings (3 times every 15 minutes) on contractions of human coronary arteries (nϭ5) elicited by acutely acting antimigraine drugs (ergotamine, OE; dihydroergotamine, ࡗ; sumatriptan, F; zolmitriptan, Ⅺ; rizatriptan, छ; naratriptan, ‚; and avitriptan, E). All drugs were administered once at a concentration 2 times their EC 50 (see Table) . Data are meanϮSEM.
potent as the parent compound in causing vasoconstriction. 41 We do not know whether active metabolites are formed by avitriptan, naratriptan, or rizatriptan. However, in view of its structural similarity to zolmitriptan, rizatriptan may be expected to form an N-desmethyl derivative, which may be pharmacologically active. Except for sumatriptan (14% to 21% plasma protein binding 40 ), we do not know the extent of plasma protein binding of the other drugs.
In conclusion, all current and prospective antimigraine drugs investigated contract the human coronary artery in vitro. Apart from avitriptan, therapeutic plasma concentrations of the drugs do not reach levels likely to cause myocardial ischemia in individuals with normal coronary circulation. However, like sumatriptan, all antimigraine compounds investigated, including the newer drugs, must remain contraindicated in patients with coronary artery disease. The sustained coronary artery contraction induced by ergotamine and dihydroergotamine is an important disadvantage compared with the sumatriptan-like drugs.
